ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

1.01
0.0245
(2.49%)
Cerrado 14 Marzo 2:00PM
1.0007
-0.0093
(-0.92%)
Fuera de horario: 4:58PM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
1.0007
Postura de Compra
1.00
Postura de Venta
1.03
Volume Operado de la Acción
739,456
1.00 Rango del Día 1.03
0.9801 Rango de 52 semanas 5.94
Capitalización de Mercado [m]
Precio Anterior
0.9855
Precio de Apertura
1.02
Última hora de negociación
Volumen financiero
US$ 750,282
Precio Promedio Ponderado
1.0146
Volumen promedio (3 m)
1,300,680
Acciones en circulación
90,552,687
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.90
Beneficio por acción (BPA)
-1.13
turnover
34.48M
Beneficio neto
-102.07M

Acerca de Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Dover, Delaware, USA
Fundado
-
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was US$0.99. Over the last year, Caribou Biosciences shares have traded in a share price range of US$ 0.9801 to US$ 5.94.

Caribou Biosciences currently has 90,552,687 shares in issue. The market capitalisation of Caribou Biosciences is US$89.24 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -0.90.

CRBU Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.1493-12.98260869571.151.170.98018609911.06008992CS
4-0.3493-25.87407407411.351.460.980110300631.20040456CS
12-0.7693-43.46327683621.772.040.980113006801.45098305CS
26-1.0993-52.34761904762.12.99950.980112904591.82255554CS
52-4.5793-82.06630824375.585.940.980116105552.43969552CS
156-8.2193-89.14642082439.2213.190.980113595534.90021261CS
260-16.6493-94.330311614717.6532.6450.980112303836.17963874CS

CRBU - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Caribou Biosciences?
El precio actual de las acciones de Caribou Biosciences es US$ 1.0007
¿Cuántas acciones de Caribou Biosciences están en circulación?
Caribou Biosciences tiene 90,552,687 acciones en circulación
¿Cuál es la capitalización de mercado de Caribou Biosciences?
La capitalización de mercado de Caribou Biosciences es USD 89.24M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Caribou Biosciences?
Caribou Biosciences ha negociado en un rango de US$ 0.9801 a US$ 5.94 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Caribou Biosciences?
El ratio precio/beneficio de Caribou Biosciences es -0.9
¿Cuál es el ratio de efectivo a ventas de Caribou Biosciences?
El ratio de efectivo a ventas de Caribou Biosciences es 2.68
¿Cuál es la moneda de reporte de Caribou Biosciences?
Caribou Biosciences presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Caribou Biosciences?
El último ingresos anual de Caribou Biosciences es USD 34.48M
¿Cuál es el último beneficio anual de Caribou Biosciences?
El último beneficio anual de Caribou Biosciences es USD -102.07M
¿Cuál es la dirección registrada de Caribou Biosciences?
La dirección registrada de Caribou Biosciences es 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
¿Cuál es la dirección del sitio web de Caribou Biosciences?
La dirección del sitio web de Caribou Biosciences es www.cariboubio.com
¿En qué sector industrial opera Caribou Biosciences?
Caribou Biosciences opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
RDUSRadius Recycling Inc
US$ 27.902
(104.26%)
8.53M
BONBon Natural Life Ltd
US$ 1.40
(90.29%)
84M
SUNESUNation Energy Inc
US$ 0.5213
(62.96%)
513.96M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 255.00
(39.80%)
222
AAOIApplied Optoelectronics Inc
US$ 22.105
(39.29%)
17.01M
GLSTUGlobal Star Acquisition Inc
US$ 2.00
(-69.23%)
421
CURRCurrenc Group Inc
US$ 2.03
(-41.33%)
1.42M
ADTXAditxt Inc
US$ 0.0201
(-39.82%)
240.2M
HEPAHepion Pharmaceuticals Inc
US$ 0.0228
(-39.68%)
161.52M
WKSPWorksport Ltd
US$ 0.36205
(-35.45%)
4.96M
SUNESUNation Energy Inc
US$ 0.5213
(62.96%)
513.96M
NVDANVIDIA Corporation
US$ 121.67
(5.27%)
277.56M
ADTXAditxt Inc
US$ 0.0201
(-39.82%)
240.2M
HEPAHepion Pharmaceuticals Inc
US$ 0.0228
(-39.68%)
161.52M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 9.225
(7.64%)
160.21M

CRBU Discussion

Ver más
TechandBio TechandBio 4 horas hace
what a piece of shit stock this you need to be very selective People got duped when

Pfizer bought some shares here at

On June 30, 2023, Pfizer invested $25 million in Caribou Biosciences, purchasing 4.69 million shares at $5.33 per share, boosting the gene-editing company's funding for its cell therapy programs.

https://www.cariboubio.com/pipeline/

Founder of CRSP on board here a lot of companies that fail in this space!

Jennifer Doudna, PhD

Jennifer is a co-founder of Caribou Biosciences. She is a professor of molecular and cell biology and chemistry at the University of California, Berkeley where she is the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences; the president of the Innovative Genomics Institute; and investigator at the Howard Hughes Medical Institute; a senior investigator at the Gladstone Institutes; a faculty scientist in the physical biosciences division of Lawrence Berkeley National Laboratory; and a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Her research seeks to understand how non-coding RNA molecules control the expression of genetic information and she has published extensively in the field of CRISPR-Cas biology. Jennifer’s work and that of her collaborator Dr. Emmanuelle Charpentier was recognized by the award of the Nobel Prize in Chemistry 2020 as well as a 2015 Breakthrough Prize. Her work on CRISPR-Cas systems has also been recognized with the Paul Janssen Award for Biomedical Research, a Lurie Prize in Biomedical Sciences, and the Princess of Asturias award. Jennifer was also named to the 2015 TIME Magazine’s TIME 100 list of the 100 most influential people in the world. After serving as a member of the Yale University faculty for eight years, during which time she was promoted to Henry Ford II Professor of Molecular Biophysics and Biochemistry, she joined the University of California, Berkeley faculty in 2002. Jennifer earned a PhD in biochemistry from Harvard University and was a postdoctoral scholar at the University of Colorado Boulder.


$CRBU
👍️0
theorysuit theorysuit 1 mes hace
What do you think of their shift to partial HLA matching?
👍️0
Monksdream Monksdream 2 meses hace
CRBU. Under $2
👍️0
Monksdream Monksdream 3 meses hace
CRBU under $2
👍️0
TrendTrade2016 TrendTrade2016 4 meses hace
CRBU READY TO BEAST
👍️0
TrendTrade2016 TrendTrade2016 4 meses hace
CRBU...NEW SCAN JUST GAVE ME THIS BIO
👍️0
Monksdream Monksdream 5 meses hace
CRBU under $3
👍️0
Monksdream Monksdream 5 meses hace
CRBU under $2
👍️0
Monksdream Monksdream 6 meses hace
CRBU under $3
👍️0
Monksdream Monksdream 8 meses hace
CRBU under $3
👍️0
jondoeuk jondoeuk 8 meses hace
Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.
👍️0
Monksdream Monksdream 8 meses hace
CRBU under $3
👍️0
Monksdream Monksdream 8 meses hace
CRBU new 52 week low
👍️0
Monksdream Monksdream 9 meses hace
CRBU new 52 week low
👍️0
NY1972 NY1972 9 meses hace
Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
👍️0
Diego Rivas Diego Rivas 9 meses hace
Any good news in here comming?
👍️0
jondoeuk jondoeuk 9 meses hace
Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
👍️0
jondoeuk jondoeuk 9 meses hace
The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
👍️0
Monksdream Monksdream 9 meses hace
CRBU new 52 week low
👍️0
stocksrising stocksrising 9 meses hace
Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
👍️0
jondoeuk jondoeuk 9 meses hace
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
👍️ 1
Monksdream Monksdream 10 meses hace
CRBU new 52 week low
👍️0
Monksdream Monksdream 10 meses hace
CRBU new 52 week low
👍️0
Monksdream Monksdream 11 meses hace
CRBU under $5
👍️0
stocksrising stocksrising 1 año hace
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
👍️0
Monksdream Monksdream 1 año hace
CRBU new 52 week low
👍️0
jondoeuk jondoeuk 2 años hace
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
👍️0
trueblue trueblue 2 años hace
.
👍️0
trueblue trueblue 2 años hace
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
👍️0
NY1972 NY1972 2 años hace
Didn't they buy TRIL? Just gambling with billions from US government.
👍️0
jondoeuk jondoeuk 2 años hace
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
👍️0
trueblue trueblue 2 años hace
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
👍️0
Monksdream Monksdream 2 años hace
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
trueblue trueblue 2 años hace
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
👍️0
Stockexpertpro Stockexpertpro 2 años hace
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
👍️0
TheFinalCD TheFinalCD 2 años hace
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
👍️0
Monksdream Monksdream 2 años hace
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Su Consulta Reciente